Targeted radionuclide therapy (TRT) is a therapeutic modality that combines the strengths of radiotherapy and systemic molecularly targeted therapy. Over the past few years, new TRT agents have been developed against an expanding array of molecular targets, particularly in cancers with limited treatment options. The authors of this Review discuss these advances, focusing on what constitutes an optimal target and discussing lessons learned from past experience in order to broaden the scope of TRT.
- Irina Primac
- Kevin Tabury
- Ken Herrmann